Aarhus University Seal / Aarhus Universitets segl

Drug delivery in intervertebral disc degeneration and osteoarthritis: Selecting the optimal platform for the delivery of disease-modifying agents

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisReviewForskningpeer review

Standard

Drug delivery in intervertebral disc degeneration and osteoarthritis : Selecting the optimal platform for the delivery of disease-modifying agents. / Colella, Fabio; Garcia, João Pedro; Sorbona, Marco; Lolli, Andrea; Antunes, Bernardo; D'Atri, Domenico; Barré, Florian P.Y.; Oieni, Jacopo; Vainieri, Maria Letizia; Zerrillo, Luana; Capar, Serdar; Häckel, Sonja; Cai, Yunpeng; Creemers, Laura B.

I: Journal of Controlled Release, Bind 328, 12.2020, s. 985-999.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisReviewForskningpeer review

Harvard

Colella, F, Garcia, JP, Sorbona, M, Lolli, A, Antunes, B, D'Atri, D, Barré, FPY, Oieni, J, Vainieri, ML, Zerrillo, L, Capar, S, Häckel, S, Cai, Y & Creemers, LB 2020, 'Drug delivery in intervertebral disc degeneration and osteoarthritis: Selecting the optimal platform for the delivery of disease-modifying agents', Journal of Controlled Release, bind 328, s. 985-999. https://doi.org/10.1016/j.jconrel.2020.08.041

APA

Colella, F., Garcia, J. P., Sorbona, M., Lolli, A., Antunes, B., D'Atri, D., Barré, F. P. Y., Oieni, J., Vainieri, M. L., Zerrillo, L., Capar, S., Häckel, S., Cai, Y., & Creemers, L. B. (2020). Drug delivery in intervertebral disc degeneration and osteoarthritis: Selecting the optimal platform for the delivery of disease-modifying agents. Journal of Controlled Release, 328, 985-999. https://doi.org/10.1016/j.jconrel.2020.08.041

CBE

Colella F, Garcia JP, Sorbona M, Lolli A, Antunes B, D'Atri D, Barré FPY, Oieni J, Vainieri ML, Zerrillo L, Capar S, Häckel S, Cai Y, Creemers LB. 2020. Drug delivery in intervertebral disc degeneration and osteoarthritis: Selecting the optimal platform for the delivery of disease-modifying agents. Journal of Controlled Release. 328:985-999. https://doi.org/10.1016/j.jconrel.2020.08.041

MLA

Vancouver

Author

Colella, Fabio ; Garcia, João Pedro ; Sorbona, Marco ; Lolli, Andrea ; Antunes, Bernardo ; D'Atri, Domenico ; Barré, Florian P.Y. ; Oieni, Jacopo ; Vainieri, Maria Letizia ; Zerrillo, Luana ; Capar, Serdar ; Häckel, Sonja ; Cai, Yunpeng ; Creemers, Laura B. / Drug delivery in intervertebral disc degeneration and osteoarthritis : Selecting the optimal platform for the delivery of disease-modifying agents. I: Journal of Controlled Release. 2020 ; Bind 328. s. 985-999.

Bibtex

@article{bdb46abab51948e89363f342cf929d6e,
title = "Drug delivery in intervertebral disc degeneration and osteoarthritis: Selecting the optimal platform for the delivery of disease-modifying agents",
abstract = "Osteoarthritis (OA) and intervertebral disc degeneration (IVDD) as major cause of chronic low back pain represent the most common degenerative joint pathologies and are leading causes of pain and disability in adults. Articular cartilage (AC) and intervertebral discs are cartilaginous tissues with a similar biochemical composition and pathophysiological aspects of degeneration. Although treatments directed at reversing these conditions are yet to be developed, many promising disease-modifying drug candidates are currently under investigation. Given the localized nature of these chronic diseases, drug delivery systems have the potential to enhance therapeutic outcomes by providing controlled and targeted release of bioactives, minimizing the number of injections needed and increasing drug concentration in the affected areas. This review provides a comprehensive overview of the currently most promising disease-modifying drugs as well as potential drug delivery systems for OA and IVDD therapy.",
author = "Fabio Colella and Garcia, {Jo{\~a}o Pedro} and Marco Sorbona and Andrea Lolli and Bernardo Antunes and Domenico D'Atri and Barr{\'e}, {Florian P.Y.} and Jacopo Oieni and Vainieri, {Maria Letizia} and Luana Zerrillo and Serdar Capar and Sonja H{\"a}ckel and Yunpeng Cai and Creemers, {Laura B.}",
note = "Publisher Copyright: {\textcopyright} 2020 The Authors Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",
year = "2020",
month = dec,
doi = "10.1016/j.jconrel.2020.08.041",
language = "English",
volume = "328",
pages = "985--999",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier BV",

}

RIS

TY - JOUR

T1 - Drug delivery in intervertebral disc degeneration and osteoarthritis

T2 - Selecting the optimal platform for the delivery of disease-modifying agents

AU - Colella, Fabio

AU - Garcia, João Pedro

AU - Sorbona, Marco

AU - Lolli, Andrea

AU - Antunes, Bernardo

AU - D'Atri, Domenico

AU - Barré, Florian P.Y.

AU - Oieni, Jacopo

AU - Vainieri, Maria Letizia

AU - Zerrillo, Luana

AU - Capar, Serdar

AU - Häckel, Sonja

AU - Cai, Yunpeng

AU - Creemers, Laura B.

N1 - Publisher Copyright: © 2020 The Authors Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2020/12

Y1 - 2020/12

N2 - Osteoarthritis (OA) and intervertebral disc degeneration (IVDD) as major cause of chronic low back pain represent the most common degenerative joint pathologies and are leading causes of pain and disability in adults. Articular cartilage (AC) and intervertebral discs are cartilaginous tissues with a similar biochemical composition and pathophysiological aspects of degeneration. Although treatments directed at reversing these conditions are yet to be developed, many promising disease-modifying drug candidates are currently under investigation. Given the localized nature of these chronic diseases, drug delivery systems have the potential to enhance therapeutic outcomes by providing controlled and targeted release of bioactives, minimizing the number of injections needed and increasing drug concentration in the affected areas. This review provides a comprehensive overview of the currently most promising disease-modifying drugs as well as potential drug delivery systems for OA and IVDD therapy.

AB - Osteoarthritis (OA) and intervertebral disc degeneration (IVDD) as major cause of chronic low back pain represent the most common degenerative joint pathologies and are leading causes of pain and disability in adults. Articular cartilage (AC) and intervertebral discs are cartilaginous tissues with a similar biochemical composition and pathophysiological aspects of degeneration. Although treatments directed at reversing these conditions are yet to be developed, many promising disease-modifying drug candidates are currently under investigation. Given the localized nature of these chronic diseases, drug delivery systems have the potential to enhance therapeutic outcomes by providing controlled and targeted release of bioactives, minimizing the number of injections needed and increasing drug concentration in the affected areas. This review provides a comprehensive overview of the currently most promising disease-modifying drugs as well as potential drug delivery systems for OA and IVDD therapy.

UR - http://www.scopus.com/inward/record.url?scp=85090558186&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2020.08.041

DO - 10.1016/j.jconrel.2020.08.041

M3 - Review

C2 - 32860929

AN - SCOPUS:85090558186

VL - 328

SP - 985

EP - 999

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

ER -